Cargando…

The relationship between glasgow prognostic score and serum tumor markers in patients with advanced non-small cell lung cancer

BACKGROUND: Glasgow Prognostic Score (GPS) has been reported as a powerful prognostic tool for patients with advanced non–small cell lung cancer (NSCLC). The aim of this study was to assess the relationship between GPS and prognosis related tumor markers in patients with advanced NSCLC. METHODS: We...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Ai-Gui, Chen, Hong-Lin, Lu, Hui-Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4432878/
https://www.ncbi.nlm.nih.gov/pubmed/25956656
http://dx.doi.org/10.1186/s12885-015-1403-x
_version_ 1782371550035443712
author Jiang, Ai-Gui
Chen, Hong-Lin
Lu, Hui-Yu
author_facet Jiang, Ai-Gui
Chen, Hong-Lin
Lu, Hui-Yu
author_sort Jiang, Ai-Gui
collection PubMed
description BACKGROUND: Glasgow Prognostic Score (GPS) has been reported as a powerful prognostic tool for patients with advanced non–small cell lung cancer (NSCLC). The aim of this study was to assess the relationship between GPS and prognosis related tumor markers in patients with advanced NSCLC. METHODS: We included 138 advanced NSCLC patients and twenty healthy controls in the study. GPS was calculated by combined serum C-reactive protein (CRP) and albumin. Three serum tumor markers, which included cytokeratin 19 fragment antigen 21-1 (CYFRA21–1), carcinoembryonic antigen (CEA) and tissue polypeptide specific antigen (TPS), were detected by enzyme-linked immunosorbent assay (ELISA). GPS and tumor markers were all assessed before chemotherapy. All patients received at least 2 courses of cisplatin-based chemotherapy. After that, 2 to 5 years follow-up was conducted. RESULTS: Median levels of CYFRA21–1 were 1.5 ng/ml (0.1–3.1 ng/ml) in healthy controls, and 4.6 ng/ml (0.7–35.2 ng/ml) in GPS 0 advanced NSCLC, 11.2 ng/ml (0.4–89.2) ng/ml in GPS 1 advanced NSCLC, and 15.7 ng/ml (2.9–134.6 ng/ml) in GPS 2 advanced NSCLC, respectively. Median levels of CYFRA21-1 were higher in NSCLC patients than in healthy controls, and CYFRA21-1 increased gradually according to GPS category in NSCLC patients (P < 0.05). Similar results were found for median levels of CEA and TPS in healthy controls and NSCLC patients (P < 0.05). In NSCLC patients, positive correlations were found between CYFRA21-1 and GPS, CEA and GPS, TPS and GPS. The Spearman’s rank correlation coefficient were 0.67 (P < 0.05), 0.61 (P < 0.05) and 0.55 (P < 0.05), respectively. Survival analyses showed GPS was an independent prognostic factor for advanced NSCLC. CYFRA21-1(>3.3 ng/ml) and TPS (>80 U/l) were related with the prognosis of advanced NSCLC by univariate analyses, but multivariate analyses showed CYFRA21-1, TPS and CEA were not the independent prognostic factors for advanced NSCLC. CONCLUSIONS: Our results showed GPS were positive correlated with CYFRA21-1, CEA and TPS in patients with advanced NSCLC. However, GPS was more efficient in predicting prognosis of advanced NSCLC than these three single prognosis related tumor markers.
format Online
Article
Text
id pubmed-4432878
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-44328782015-05-16 The relationship between glasgow prognostic score and serum tumor markers in patients with advanced non-small cell lung cancer Jiang, Ai-Gui Chen, Hong-Lin Lu, Hui-Yu BMC Cancer Research Article BACKGROUND: Glasgow Prognostic Score (GPS) has been reported as a powerful prognostic tool for patients with advanced non–small cell lung cancer (NSCLC). The aim of this study was to assess the relationship between GPS and prognosis related tumor markers in patients with advanced NSCLC. METHODS: We included 138 advanced NSCLC patients and twenty healthy controls in the study. GPS was calculated by combined serum C-reactive protein (CRP) and albumin. Three serum tumor markers, which included cytokeratin 19 fragment antigen 21-1 (CYFRA21–1), carcinoembryonic antigen (CEA) and tissue polypeptide specific antigen (TPS), were detected by enzyme-linked immunosorbent assay (ELISA). GPS and tumor markers were all assessed before chemotherapy. All patients received at least 2 courses of cisplatin-based chemotherapy. After that, 2 to 5 years follow-up was conducted. RESULTS: Median levels of CYFRA21–1 were 1.5 ng/ml (0.1–3.1 ng/ml) in healthy controls, and 4.6 ng/ml (0.7–35.2 ng/ml) in GPS 0 advanced NSCLC, 11.2 ng/ml (0.4–89.2) ng/ml in GPS 1 advanced NSCLC, and 15.7 ng/ml (2.9–134.6 ng/ml) in GPS 2 advanced NSCLC, respectively. Median levels of CYFRA21-1 were higher in NSCLC patients than in healthy controls, and CYFRA21-1 increased gradually according to GPS category in NSCLC patients (P < 0.05). Similar results were found for median levels of CEA and TPS in healthy controls and NSCLC patients (P < 0.05). In NSCLC patients, positive correlations were found between CYFRA21-1 and GPS, CEA and GPS, TPS and GPS. The Spearman’s rank correlation coefficient were 0.67 (P < 0.05), 0.61 (P < 0.05) and 0.55 (P < 0.05), respectively. Survival analyses showed GPS was an independent prognostic factor for advanced NSCLC. CYFRA21-1(>3.3 ng/ml) and TPS (>80 U/l) were related with the prognosis of advanced NSCLC by univariate analyses, but multivariate analyses showed CYFRA21-1, TPS and CEA were not the independent prognostic factors for advanced NSCLC. CONCLUSIONS: Our results showed GPS were positive correlated with CYFRA21-1, CEA and TPS in patients with advanced NSCLC. However, GPS was more efficient in predicting prognosis of advanced NSCLC than these three single prognosis related tumor markers. BioMed Central 2015-05-10 /pmc/articles/PMC4432878/ /pubmed/25956656 http://dx.doi.org/10.1186/s12885-015-1403-x Text en © Jiang et al.; licensee BioMed Central. 2015 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Jiang, Ai-Gui
Chen, Hong-Lin
Lu, Hui-Yu
The relationship between glasgow prognostic score and serum tumor markers in patients with advanced non-small cell lung cancer
title The relationship between glasgow prognostic score and serum tumor markers in patients with advanced non-small cell lung cancer
title_full The relationship between glasgow prognostic score and serum tumor markers in patients with advanced non-small cell lung cancer
title_fullStr The relationship between glasgow prognostic score and serum tumor markers in patients with advanced non-small cell lung cancer
title_full_unstemmed The relationship between glasgow prognostic score and serum tumor markers in patients with advanced non-small cell lung cancer
title_short The relationship between glasgow prognostic score and serum tumor markers in patients with advanced non-small cell lung cancer
title_sort relationship between glasgow prognostic score and serum tumor markers in patients with advanced non-small cell lung cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4432878/
https://www.ncbi.nlm.nih.gov/pubmed/25956656
http://dx.doi.org/10.1186/s12885-015-1403-x
work_keys_str_mv AT jiangaigui therelationshipbetweenglasgowprognosticscoreandserumtumormarkersinpatientswithadvancednonsmallcelllungcancer
AT chenhonglin therelationshipbetweenglasgowprognosticscoreandserumtumormarkersinpatientswithadvancednonsmallcelllungcancer
AT luhuiyu therelationshipbetweenglasgowprognosticscoreandserumtumormarkersinpatientswithadvancednonsmallcelllungcancer
AT jiangaigui relationshipbetweenglasgowprognosticscoreandserumtumormarkersinpatientswithadvancednonsmallcelllungcancer
AT chenhonglin relationshipbetweenglasgowprognosticscoreandserumtumormarkersinpatientswithadvancednonsmallcelllungcancer
AT luhuiyu relationshipbetweenglasgowprognosticscoreandserumtumormarkersinpatientswithadvancednonsmallcelllungcancer